Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Active not recruiting 2Completed 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Carcinoma, Non-Small-Cell Lung 147Melanoma 122Breast Neoplasms 98Squamous Cell Carcinoma of Head and Neck 96Triple Negative Breast Neoplasms 85Lung Neoplasms 64Neoplasm Metastasis 53Carcinoma, Renal Cell 49Neoplasms 46Head and Neck Neoplasms 46Colorectal Neoplasms 41Ovarian Neoplasms 38Carcinoma, Transitional Cell 37Carcinoma, Hepatocellular 36Pancreatic Neoplasms 35Urinary Bladder Neoplasms 34Recurrence 33Stomach Neoplasms 32Glioblastoma 30Brain Neoplasms 28Sarcoma 26Endometrial Neoplasms 25Prostatic Neoplasms 23Hodgkin Disease 22Uterine Cervical Neoplasms 19Fallopian Tube Neoplasms 19Carcinoma, Squamous Cell 19Esophageal Squamous Cell Carcinoma 17Adenocarcinoma 17Multiple Myeloma 16

Interventions

Gemcitabine 11Cisplatin 11Nivolumab 4Doxorubicin 4pembrolizumab 3avelumab 3Radiotherapy 3Fluorouracil 3Docetaxel 3Carboplatin 3vinflunine 2pegfilgrastim 2Sunitinib 2Platinum 2Paclitaxel 2Immunoglobulin G 2Ifosfamide 2Disulfides 21,2-diaminocyclohexaneplatinum II citrate 2vandetanib 1tremelimumab 1tocilizumab 1temsirolimus 1tamibarotene 1relatlimab 1merphos 1guadecitabine 1enzalutamide 1durvalumab 1dehydroftorafur 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Urethral Neoplasms × pembrolizumab × Clear all
NCT04848519 2026-02-19

Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma

Emory University

Phase 2 Active not recruiting
6 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT03582475 2025-11-12

Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate

Jonsson Comprehensive Cancer Center

Phase 1 Active not recruiting
15 enrolled 17 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Prostatic Neoplasms, Urethral Neoplasms

NCT02437370 2022-10-18

Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer

University of California, Davis

Phase 1 Completed
32 enrolled
Genitourinary

Urinary Bladder Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡